NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CD8 Reactivity to Microorganisms in Blood and Breast Milk

Terminated

Conditions: Lyme Disease
Tuberculosis
Leprosy
Immune Modulation
Pertussis

First Posted Date: 2017-03-21

Last Posted Date: 2019-11-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT03084614

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Dose Escalation PfSPZ-CVac

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Pyrimethamine
Drug: Chloroquine Phosphate
Biological: Sanaria PfSPZ Challenge

First Posted Date: 2017-03-20

Last Posted Date: 2021-06-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 55

Registration Number: NCT03083847

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Phase 2

Completed

Conditions: Influenza
Influenza Immunisation

Interventions: Biological: Influenza Multimeric-001 Vaccine
Other: Placebo
Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine

First Posted Date: 2017-02-23

Last Posted Date: 2020-06-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT03058692

Locations: 🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States
🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States
🇺🇸
Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States

Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine

Phase 1

Completed

Conditions: Mosquito-Borne Disease

Interventions: Biological: AGS-v
Other: Placebo
Biological: AGS-v + adjuvant

First Posted Date: 2017-02-16

Last Posted Date: 2020-08-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 49

Registration Number: NCT03055000

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

Phase 1

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Biological: VRC-RSVRGP084-00-VP
Other: Aluminum Hydroxide Suspension

First Posted Date: 2017-02-10

Last Posted Date: 2020-10-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 95

Registration Number: NCT03049488

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Dolutegravir
Drug: Efavirenz/emtricitabine/tenofovir disoproxil fumarate
Drug: Emtricitabine/tenofovir alafenamide
Drug: Emtricitabine/tenofovir disoproxil fumarate

First Posted Date: 2017-02-09

Last Posted Date: 2022-11-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 643

Registration Number: NCT03048422

Locations: 🇧🇼
Molepolole CRS, Gaborone, Botswana
🇹🇭
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand
🇿🇼
St Mary's CRS, Chitungwiza, Zimbabwe

and more 18 locations

Etiology of Eczema Herpeticum (EH)

Completed

Conditions: Eczema Herpeticum

First Posted Date: 2017-02-01

Last Posted Date: 2021-01-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 69

Registration Number: NCT03038932

Locations: 🇺🇸
National Jewish Health: Division of Pediatric Allergy and Clinical Immunology, Denver, Colorado, United States

Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Helminthic Infection

Interventions: Drug: Oxfendazole

First Posted Date: 2017-01-30

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT03035760

Locations: 🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States

Phase I Trial of Measles Vectored Chikungungya Vaccine

Phase 1

Completed

Conditions: Chikungunya Virus Infection

Interventions: Other: Placebo
Biological: VRC-CHKVLP059-00-VP

First Posted Date: 2017-01-23

Last Posted Date: 2020-11-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 180

Registration Number: NCT03028441

Locations: 🇺🇸
Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States
🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States
🇺🇸
Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: Roseomonas mucosa

First Posted Date: 2017-01-12

Last Posted Date: 2019-11-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 31

Registration Number: NCT03018275

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy